<p>隨着我們進入 2026 年 1 月，亞洲市場正在應對一個充滿對人工智能的樂觀情緒和對經濟增長預測謹慎的環境，尤其是在中國和日本。在這樣的環境中，識別被低估的股票可以為尋求利用市場低效的投資者提供潛在機會。</p>
<h3>基於現金流的亞洲十大被低估股票</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估算）</strong></td>
<td><strong>折扣（估算）</strong></td>
</tr>
<tr>
<td>Visional (TSE:4194)</td>
<td>¥10010.00</td>
<td>¥19887.98</td>
<td>49.7%</td>
</tr>
<tr>
<td>Takara Bio (TSE:4974)</td>
<td>¥795.00</td>
<td>¥1580.06</td>
<td>49.7%</td>
</tr>
<tr>
<td>Nan Juen International (TPEX:6584)</td>
<td>NT$347.00</td>
<td>NT$687.14</td>
<td>49.5%</td>
</tr>
<tr>
<td>Kuraray (TSE:3405)</td>
<td>¥1587.00</td>
<td>¥3163.27</td>
<td>49.8%</td>
</tr>
<tr>
<td>JINS HOLDINGS (TSE:3046)</td>
<td>¥5530.00</td>
<td>¥11032.70</td>
<td>49.9%</td>
</tr>
<tr>
<td>Innovent Biologics (SEHK:1801)</td>
<td>HK$76.25</td>
<td>HK$151.11</td>
<td>49.5%</td>
</tr>
<tr>
<td>Forth Corporation (SET:FORTH)</td>
<td>THB5.75</td>
<td>THB11.21</td>
<td>48.7%</td>
</tr>
<tr>
<td>Daiichi Sankyo Company (TSE:4568)</td>
<td>¥3348.00</td>
<td>¥6544.37</td>
<td>48.8%</td>
</tr>
<tr>
<td>CURVES HOLDINGS (TSE:7085)</td>
<td>¥801.00</td>
<td>¥1581.79</td>
<td>49.4%</td>
</tr>
<tr>
<td>Aidma Holdings (TSE:7373)</td>
<td>¥3160.00</td>
<td>¥6305.80</td>
<td>49.9%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們基於現金流的 260 只被低估的亞洲股票的完整列表。</p>
<p>讓我們深入探討一些篩選出的優質選擇。</p>
<h2>CLASSYS (KOSDAQ:A214150)</h2>
<p><strong>概述：</strong> CLASSYS Inc. 是一家全球醫療美容設備提供商，市值為 3.56 萬億韓元。</p>
<p><strong>運營：</strong> 該公司主要通過其外科和醫療設備部門產生收入，金額為 3178 億韓元。</p>
<p><strong>公允價值折扣估算：</strong> 42%</p>
<p>CLASSYS 的交易價格顯著低於其估算的公允價值 94,028.53 韓元，折扣達到 42%。儘管 2025 年第三季度銷售略有下降，但淨收入與去年相比增長了兩倍多。過去一年，收益增長了 39.1%，預計將以 30.9% 的年率繼續顯著增長。分析師一致認為，價格有潛在上漲約 33.8%。</p>
<ul>
<li>根據我們的收益增長報告，CLASSYS 可能準備擴展。</li>
<li>通過我們的全面財務健康報告深入瞭解 CLASSYS 的具體情況。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0b611d0d-1cc3-4214-96d4-f413526dfa5f/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0b611d0d-1cc3-4214-96d4-f413526dfa5f/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>KOSDAQ:A214150 截至 2026 年 1 月的折現現金流</p>
<h2>北汽福田汽車有限公司 (SHSE:600166)</h2>
<p><strong>概述：</strong> 北汽福田汽車有限公司從事全球商用車的製造和銷售，市值為 231.2 億人民幣。</p>
<p><strong>運營：</strong> 北汽福田汽車有限公司通過其全球商用車製造和銷售業務產生收入。</p>
<p><strong>公允價值折扣估算：</strong> 34%</p>
<p>北汽福田汽車有限公司的交易價格為 2.92 元人民幣，顯著低於其估算的公允價值 4.43 元人民幣，表明基於現金流的潛在低估。該公司過去一年收益增長了 37.6%，預計將以 39.14% 的年率增長，超過中國市場 27.5% 的平均增長率。最近在新能源車平台上的創新突顯了福田在可持續物流解決方案上的戰略重點，可能增強未來的現金流和盈利能力。</p>
<ul>
<li>我們的北汽福田汽車有限公司增長報告中的分析暗示未來財務表現強勁。</li>
<li>通過閲讀我們的健康報告，深入瞭解北汽福田汽車有限公司的資產負債表。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/39388ef9-2d0b-4a73-8167-7e0f574839c7/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/39388ef9-2d0b-4a73-8167-7e0f574839c7/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SHSE:600166 截至 2026 年 1 月的折現現金流</p>
<h2>廈門特寶生物科技有限公司 (SHSE:688278)</h2>
<p><strong>概述：</strong> 廈門特寶生物科技有限公司專注於重組蛋白藥物的研究、開發、生產和銷售，市值為 341.6 億人民幣。</p>
<p><strong>運營：</strong> 該公司的收入主要來自其生物製藥部門，產生了 33.4 億人民幣。</p>
<p><strong>公允價值折扣估算：</strong> 48.5%</p>
<p>廈門特寶生物科技的交易價格為 83.68 元人民幣，遠低於其估算的公允價值 162.36 元人民幣，表明其基於現金流的低估。該公司過去一年收益增長了 26.9%，預計將以 34.1% 的年率顯著增長，超過中國市場 27.5% 的平均增長率。儘管非現金收益較高，但強勁的收入增長預測和高股本回報率的預期支持其改善財務表現的潛力。</p>
<ul>
<li>我們編制的增長報告表明，廈門特寶生物科技的未來前景可能向好。</li>
<li>在這份財務健康報告中解鎖我們對廈門特寶生物科技股票分析的全面見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/21048bb0-3258-4ed1-9566-6eac36ea690b/chart/dcf/query-dGhlbWU9bGlnaHQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/21048bb0-3258-4ed1-9566-6eac36ea690b/chart/dcf/query-dGhlbWU9bGlnaHQ"/></p>
<p>SHSE:688278 截至 2026 年 1 月的折現現金流</p>
<h2>抓住機會</h2>
<ul>
<li>通過使用我們的篩選器，深入瞭解所有 260 只基於現金流的被低估的亞洲股票。</li>
<li>是這些公司的股東之一嗎？確保您不會錯過任何重要的股票動態，通過在 Simply Wall St 中添加您的投資組合來獲得及時提醒。</li>
<li>Simply Wall St 是一款為長期股票投資者設計的革命性應用，免費且覆蓋全球所有市場。</li>
</ul>
<h2>準備好不同的投資方式嗎？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過提供可靠的收入來源來分散您的投資組合，以應對潛在的市場動盪。</li>
<li>通過分析師和管理層的樂觀展望，推動您的投資組合中顯示強勁增長潛力的公司。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。它不構成買賣任何股票的推薦，也未考慮您的目標或財務狀況。</strong> 我們旨在為您帶來以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>
<p>國防與災難的移動基礎設施</p>
<p>下一波機器人技術不是類人型的。它是完全自主的塔樓，在 30 分鐘內提供 5G、ISR 和雷達服務，覆蓋任何地方。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>代表 CiTech 贊助</p>

特寶生物

福田汽車

<p>截至 2026 年 1 月，亞洲市場對人工智能持樂觀態度，但對經濟增長保持謹慎，尤其是在中國和日本。投資者被鼓勵探索被低估的股票，其中值得關注的包括 CLASSYS、北汽福田汽車和廈門特寶生物，這些股票的交易價格均顯著低於其估計的公允價值。CLASSYS 的折扣為 42%，北汽福田為 34%，廈門特寶生物為 48.5%。這些公司展現出強勁的盈利增長潛力，使其成為尋求當前市場機會的投資者的吸引選項</p>

<p>As we enter January 2026, Asian markets are navigating a landscape marked by optimism around artificial intelligence and cautious economic growth forecasts, particularly in China and Japan. In such an environment, identifying undervalued stocks can offer potential opportunities for investors seeking to capitalize on market inefficiencies.</p>
<div class="lb-trans"><p>隨着我們進入 2026 年 1 月，亞洲市場正在應對一個充滿對人工智能的樂觀情緒和對經濟增長預測謹慎的環境，尤其是在中國和日本。在這樣的環境中，識別被低估的股票可以為尋求利用市場低效的投資者提供潛在機會。</p>
</div><h3>Top 10 Undervalued Stocks Based On Cash Flows In Asia</h3>
<div class="lb-trans"><h3>基於現金流的亞洲十大被低估股票</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Current Price</strong></td>
<td><strong>Fair Value (Est)</strong></td>
<td><strong>Discount (Est)</strong></td>
</tr>
<tr>
<td>Visional (TSE:4194)</td>
<td>¥10010.00</td>
<td>¥19887.98</td>
<td>49.7%</td>
</tr>
<tr>
<td>Takara Bio (TSE:4974)</td>
<td>¥795.00</td>
<td>¥1580.06</td>
<td>49.7%</td>
</tr>
<tr>
<td>Nan Juen International (TPEX:6584)</td>
<td>NT$347.00</td>
<td>NT$687.14</td>
<td>49.5%</td>
</tr>
<tr>
<td>Kuraray (TSE:3405)</td>
<td>¥1587.00</td>
<td>¥3163.27</td>
<td>49.8%</td>
</tr>
<tr>
<td>JINS HOLDINGS (TSE:3046)</td>
<td>¥5530.00</td>
<td>¥11032.70</td>
<td>49.9%</td>
</tr>
<tr>
<td>Innovent Biologics (SEHK:1801)</td>
<td>HK$76.25</td>
<td>HK$151.11</td>
<td>49.5%</td>
</tr>
<tr>
<td>Forth Corporation (SET:FORTH)</td>
<td>THB5.75</td>
<td>THB11.21</td>
<td>48.7%</td>
</tr>
<tr>
<td>Daiichi Sankyo Company (TSE:4568)</td>
<td>¥3348.00</td>
<td>¥6544.37</td>
<td>48.8%</td>
</tr>
<tr>
<td>CURVES HOLDINGS (TSE:7085)</td>
<td>¥801.00</td>
<td>¥1581.79</td>
<td>49.4%</td>
</tr>
<tr>
<td>Aidma Holdings (TSE:7373)</td>
<td>¥3160.00</td>
<td>¥6305.80</td>
<td>49.9%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>當前價格</strong></td>
<td><strong>公允價值（估算）</strong></td>
<td><strong>折扣（估算）</strong></td>
</tr>
<tr>
<td>Visional (TSE:4194)</td>
<td>¥10010.00</td>
<td>¥19887.98</td>
<td>49.7%</td>
</tr>
<tr>
<td>Takara Bio (TSE:4974)</td>
<td>¥795.00</td>
<td>¥1580.06</td>
<td>49.7%</td>
</tr>
<tr>
<td>Nan Juen International (TPEX:6584)</td>
<td>NT$347.00</td>
<td>NT$687.14</td>
<td>49.5%</td>
</tr>
<tr>
<td>Kuraray (TSE:3405)</td>
<td>¥1587.00</td>
<td>¥3163.27</td>
<td>49.8%</td>
</tr>
<tr>
<td>JINS HOLDINGS (TSE:3046)</td>
<td>¥5530.00</td>
<td>¥11032.70</td>
<td>49.9%</td>
</tr>
<tr>
<td>Innovent Biologics (SEHK:1801)</td>
<td>HK$76.25</td>
<td>HK$151.11</td>
<td>49.5%</td>
</tr>
<tr>
<td>Forth Corporation (SET:FORTH)</td>
<td>THB5.75</td>
<td>THB11.21</td>
<td>48.7%</td>
</tr>
<tr>
<td>Daiichi Sankyo Company (TSE:4568)</td>
<td>¥3348.00</td>
<td>¥6544.37</td>
<td>48.8%</td>
</tr>
<tr>
<td>CURVES HOLDINGS (TSE:7085)</td>
<td>¥801.00</td>
<td>¥1581.79</td>
<td>49.4%</td>
</tr>
<tr>
<td>Aidma Holdings (TSE:7373)</td>
<td>¥3160.00</td>
<td>¥6305.80</td>
<td>49.9%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 260 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們基於現金流的 260 只被低估的亞洲股票的完整列表。</p>
</div><p>Let's dive into some prime choices out of the screener.</p>
<div class="lb-trans"><p>讓我們深入探討一些篩選出的優質選擇。</p>
</div><h2>CLASSYS (KOSDAQ:A214150)</h2>
<div class="lb-trans"><h2>CLASSYS (KOSDAQ:A214150)</h2>
</div><p><strong>Overview:</strong> CLASSYS Inc. is a global provider of medical aesthetics devices with a market capitalization of ₩3.56 trillion.</p>
<div class="lb-trans"><p><strong>概述：</strong> CLASSYS Inc. 是一家全球醫療美容設備提供商，市值為 3.56 萬億韓元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily from its Surgical &amp; Medical Equipment segment, amounting to ₩317.80 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過其外科和醫療設備部門產生收入，金額為 3178 億韓元。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 42%</p>
<div class="lb-trans"><p><strong>公允價值折扣估算：</strong> 42%</p>
</div><p>CLASSYS is trading at a significant discount, 42% below its estimated fair value of ₩94,028.53. Despite a slight decline in sales for the third quarter of 2025, net income more than doubled compared to the previous year. Earnings have grown by 39.1% over the past year and are expected to continue growing significantly at an annual rate of 30.9%. Analysts agree on a potential price increase of about 33.8%.</p>
<div class="lb-trans"><p>CLASSYS 的交易價格顯著低於其估算的公允價值 94,028.53 韓元，折扣達到 42%。儘管 2025 年第三季度銷售略有下降，但淨收入與去年相比增長了兩倍多。過去一年，收益增長了 39.1%，預計將以 30.9% 的年率繼續顯著增長。分析師一致認為，價格有潛在上漲約 33.8%。</p>
</div><ul>
<li>According our earnings growth report, there's an indication that CLASSYS might be ready to expand.</li>
<li>Dive into the specifics of CLASSYS here with our thorough financial health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>根據我們的收益增長報告，CLASSYS 可能準備擴展。</li>
<li>通過我們的全面財務健康報告深入瞭解 CLASSYS 的具體情況。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0b611d0d-1cc3-4214-96d4-f413526dfa5f/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/0b611d0d-1cc3-4214-96d4-f413526dfa5f/chart/dcf?theme=light"/></p>
<p>KOSDAQ:A214150 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>KOSDAQ:A214150 截至 2026 年 1 月的折現現金流</p>
</div><h2>Beiqi Foton MotorLtd (SHSE:600166)</h2>
<div class="lb-trans"><h2>北汽福田汽車有限公司 (SHSE:600166)</h2>
</div><p><strong>Overview:</strong> Beiqi Foton Motor Co., Ltd. is involved in the manufacture and sale of commercial vehicles globally, with a market cap of CN¥23.12 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 北汽福田汽車有限公司從事全球商用車的製造和銷售，市值為 231.2 億人民幣。</p>
</div><p><strong>Operations:</strong> Beiqi Foton Motor Co., Ltd. generates revenue through its global operations in the commercial vehicle manufacturing and sales sector.</p>
<div class="lb-trans"><p><strong>運營：</strong> 北汽福田汽車有限公司通過其全球商用車製造和銷售業務產生收入。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 34%</p>
<div class="lb-trans"><p><strong>公允價值折扣估算：</strong> 34%</p>
</div><p>Beiqi Foton Motor Ltd. is trading at CN¥2.92, significantly below its estimated fair value of CN¥4.43, indicating a potential undervaluation based on cash flows. The company's earnings have grown by 37.6% over the past year and are forecast to grow at 39.14% annually, outpacing the Chinese market's average growth rate of 27.5%. Recent innovations in new energy vehicle platforms highlight Foton's strategic focus on sustainable logistics solutions, potentially enhancing future cash flows and profitability.</p>
<div class="lb-trans"><p>北汽福田汽車有限公司的交易價格為 2.92 元人民幣，顯著低於其估算的公允價值 4.43 元人民幣，表明基於現金流的潛在低估。該公司過去一年收益增長了 37.6%，預計將以 39.14% 的年率增長，超過中國市場 27.5% 的平均增長率。最近在新能源車平台上的創新突顯了福田在可持續物流解決方案上的戰略重點，可能增強未來的現金流和盈利能力。</p>
</div><ul>
<li>The analysis detailed in our Beiqi Foton MotorLtd growth report hints at robust future financial performance.</li>
<li>Get an in-depth perspective on Beiqi Foton MotorLtd's balance sheet by reading our health report here.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們的北汽福田汽車有限公司增長報告中的分析暗示未來財務表現強勁。</li>
<li>通過閲讀我們的健康報告，深入瞭解北汽福田汽車有限公司的資產負債表。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/39388ef9-2d0b-4a73-8167-7e0f574839c7/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/39388ef9-2d0b-4a73-8167-7e0f574839c7/chart/dcf?theme=light"/></p>
<p>SHSE:600166 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>SHSE:600166 截至 2026 年 1 月的折現現金流</p>
</div><h2>Xiamen Amoytop Biotech (SHSE:688278)</h2>
<div class="lb-trans"><h2>廈門特寶生物科技有限公司 (SHSE:688278)</h2>
</div><p><strong>Overview:</strong> Xiamen Amoytop Biotech Co., Ltd. focuses on the research, development, production, and sale of recombinant protein drugs both in China and internationally, with a market cap of CN¥34.16 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 廈門特寶生物科技有限公司專注於重組蛋白藥物的研究、開發、生產和銷售，市值為 341.6 億人民幣。</p>
</div><p><strong>Operations:</strong> The company's revenue is primarily derived from its biologics segment, which generated CN¥3.34 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司的收入主要來自其生物製藥部門，產生了 33.4 億人民幣。</p>
</div><p><strong>Estimated Discount To Fair Value:</strong> 48.5%</p>
<div class="lb-trans"><p><strong>公允價值折扣估算：</strong> 48.5%</p>
</div><p>Xiamen Amoytop Biotech is trading at CN¥83.68, well below its estimated fair value of CN¥162.36, suggesting it is undervalued based on cash flows. The company's earnings have grown by 26.9% over the past year and are forecast to grow significantly at 34.1% annually, surpassing the Chinese market's average growth rate of 27.5%. Despite high non-cash earnings, strong revenue growth projections and a high return on equity forecast support its potential for improved financial performance.</p>
<div class="lb-trans"><p>廈門特寶生物科技的交易價格為 83.68 元人民幣，遠低於其估算的公允價值 162.36 元人民幣，表明其基於現金流的低估。該公司過去一年收益增長了 26.9%，預計將以 34.1% 的年率顯著增長，超過中國市場 27.5% 的平均增長率。儘管非現金收益較高，但強勁的收入增長預測和高股本回報率的預期支持其改善財務表現的潛力。</p>
</div><ul>
<li>The growth report we've compiled suggests that Xiamen Amoytop Biotech's future prospects could be on the up.</li>
<li>Unlock comprehensive insights into our analysis of Xiamen Amoytop Biotech stock in this financial health report.</li>
</ul>
<div class="lb-trans"><ul>
<li>我們編制的增長報告表明，廈門特寶生物科技的未來前景可能向好。</li>
<li>在這份財務健康報告中解鎖我們對廈門特寶生物科技股票分析的全面見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/21048bb0-3258-4ed1-9566-6eac36ea690b/chart/dcf/query-dGhlbWU9bGlnaHQ" alt="" original-src="https://images.simplywall.st/company/21048bb0-3258-4ed1-9566-6eac36ea690b/chart/dcf?theme=light"/></p>
<p>SHSE:688278 Discounted Cash Flow as at Jan 2026</p>
<div class="lb-trans"><p>SHSE:688278 截至 2026 年 1 月的折現現金流</p>
</div><h2>Seize The Opportunity</h2>
<div class="lb-trans"><h2>抓住機會</h2>
</div><ul>
<li>Get an in-depth perspective on all 260 Undervalued Asian Stocks Based On Cash Flows by using our screener here.</li>
<li>Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.</li>
<li>Simply Wall St is a revolutionary app designed for long-term stock investors, it's free and covers every market in the world.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過使用我們的篩選器，深入瞭解所有 260 只基於現金流的被低估的亞洲股票。</li>
<li>是這些公司的股東之一嗎？確保您不會錯過任何重要的股票動態，通過在 Simply Wall St 中添加您的投資組合來獲得及時提醒。</li>
<li>Simply Wall St 是一款為長期股票投資者設計的革命性應用，免費且覆蓋全球所有市場。</li>
</ul>
</div><h2>Ready For A Different Approach?</h2>
<div class="lb-trans"><h2>準備好不同的投資方式嗎？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>通過提供可靠的收入來源來分散您的投資組合，以應對潛在的市場動盪。</li>
<li>通過分析師和管理層的樂觀展望，推動您的投資組合中顯示強勁增長潛力的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation.</strong> We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們提供的評論基於歷史數據和分析師預測，僅使用無偏見的方法，我們的文章並不旨在提供財務建議。它不構成買賣任何股票的推薦，也未考慮您的目標或財務狀況。</strong> 我們旨在為您帶來以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>國防與災難的移動基礎設施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是類人型的。它是完全自主的塔樓，在 30 分鐘內提供 5G、ISR 和雷達服務，覆蓋任何地方。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 贊助</p>
</div>

2026 年 1 月預計被低估的 3 只亞洲股票